HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

Core Insights - HUTCHMED is set to present new data from the ESLIM-01 Phase III trial of sovleplenib and other investigator-initiated studies at major upcoming medical conferences, including the ASH Annual Meeting and ESMO Asia Congress in December 2024 [1][4] Group 1: ESLIM-01 Phase III Trial Data - Long-term safety and efficacy data from the ESLIM-01 Phase III study of sovleplenib in adult patients with chronic primary immune thrombocytopenia (ITP) will be reported, with 179 patients treated as of January 31, 2024 [2][3] - The overall response rate for patients was 81% (145/179), with a durable response rate of 51.4% and a long-term durable response rate of 59.8% [3] Group 2: Upcoming Presentations - The ASH Annual Meeting will feature a follow-on sub-study demonstrating the effectiveness of long-term treatment with sovleplenib in maintaining platelet counts in adults with chronic primary ITP [2][3] - The ESMO Asia Congress will include studies on fruquintinib combined with serplulimab for advanced non-clear cell renal cell carcinoma and other cancer treatments [4][6] Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, employing approximately 5,000 personnel [7]